Alecensa® (alectinib)
(Oral)

I. Length of Authorization
Coverage will be provided for six months and may be renewed.

II. Dosing Limits
A. Quantity Limit (max daily dose) [Pharmacy Benefit]:
   - Alecensa 150 mg capsule: 8 capsules per day
B. Max Units (per dose and over time) [Medical Benefit]:
   - 1200 mg per day

III. Initial Approval Criteria
Coverage is provided in the following conditions:
- Patient is at least 18 years old; AND
- Must be used as a single agent; AND
- Patient’s disease is anaplastic lymphoma kinase (ALK)-positive as detected by FDA-approved test*; AND

Non-small Cell Lung Cancer †
- Patient’s disease is recurrent, advanced or metastatic (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease): AND
  - Used as first line therapy; OR
  - Used in patients who are intolerant to crizotinib; OR
  - Used as subsequent therapy to crizotinib (except in cases of symptomatic systemic disease with an isolated lesion); OR
  - Used as continuation of first line therapy (except for symptomatic progression with multiple lesions)

Central Nervous System Cancers ‡
- Patient has brain metastases from ALK-positive non-small cell lung cancer: AND
  - Patient has newly diagnosed brain metastases and stable systemic disease or reasonable systemic treatment options; OR
  - Patient has recurrent brain metastases

*http://www.fda.gov/CompanionDiagnostics
IV. **Renewal Criteria**

Authorizations can be renewed based on the following criteria:

- Patient continues to meet the criteria identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe elevations in ALT/AST or bilirubin, severe myalgia, bradycardia, interstitial lung disease/pneumonitis, severe elevations in creatine phosphokinase (CPK), severe renal impairment, etc.

V. **Dosage/Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Indications</td>
<td>Administer 600 mg (4 capsules) by mouth twice daily, with food, until disease progression or unacceptable toxicity.</td>
</tr>
</tbody>
</table>

VI. **Billing Code/Availability Information**

**HCPCS code:**
- J8999: Prescription drug, oral, chemotherapeutic, not otherwise specified
- C9399: Unclassified drugs or biologicals (**Hospital Outpatient Use ONLY**)

**NDC:**
- Alecensa 150 mg capsule: 50242-0130-xx

VII. **References**

2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for alectinib. National Comprehensive Cancer Network, 2019. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2019.

**Appendix 1 – Covered Diagnosis Codes**

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C33</td>
<td>Malignant neoplasm of trachea</td>
</tr>
<tr>
<td>C34.00</td>
<td>Malignant neoplasm of unspecified main bronchus</td>
</tr>
<tr>
<td>C34.01</td>
<td>Malignant neoplasm of right main bronchus</td>
</tr>
<tr>
<td>C34.02</td>
<td>Malignant neoplasm of left main bronchus</td>
</tr>
<tr>
<td>C34.10</td>
<td>Malignant neoplasm of upper lobe, unspecified bronchus or lung</td>
</tr>
<tr>
<td>C34.11</td>
<td>Malignant neoplasm of upper lobe, right bronchus or lung</td>
</tr>
</tbody>
</table>
ICD-10 | ICD-10 Description
---|---
C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung
C34.2 | Malignant neoplasm of middle lobe, bronchus or lung
C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung
C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung
C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus or lung
C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung
C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung
C79.31 | Secondary malignant neoplasm of brain
Z85.118 | Personal history of other malignant neoplasm of bronchus and lung

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: [http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx](http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx). Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto Government Benefit Administrators, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>